Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to 907.37%.

  • Agios Pharmaceuticals' EBITDA Margin rose 2395600.0% to 907.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 1061.8%, marking a year-over-year increase of 1763000.0%. This contributed to the annual value of 1166.47% for FY2024, which is 2930500.0% up from last year.
  • Agios Pharmaceuticals' EBITDA Margin amounted to 907.37% in Q3 2025, which was up 2395600.0% from 1020.12% recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' EBITDA Margin peaked at 907.37% during Q3 2025, and registered a low of 12156.85% during Q1 2022.
  • Over the past 4 years, Agios Pharmaceuticals' median EBITDA Margin value was 1363.66% (recorded in 2023), while the average stood at 2165.56%.
  • Per our database at Business Quant, Agios Pharmaceuticals' EBITDA Margin skyrocketed by 105413600bps in 2023 and then plummeted by -976300bps in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' EBITDA Margin (Quarter) stood at 2300.97% in 2022, then skyrocketed by 35bps to 1496.23% in 2023, then grew by 22bps to 1165.3% in 2024, then grew by 22bps to 907.37% in 2025.
  • Its last three reported values are 907.37% in Q3 2025, 1020.12% for Q2 2025, and 1221.97% during Q1 2025.